Dana-Farber Cancer Institute
Avatar

2019 ESMO Metastatic Bladder Cancer Update: Atezolizumab + Gemcitabine-Platinum, Enfortumab Vedotin + Pembro, Sacituzumab Govitecan, Durvalumab + FGFR, mTOR or PARPi), Neoadjuvant Ipi + Nivo

By Dana-Farber Cancer Institute FEATURING Guru Sonpavde
By Dana-Farber Cancer Institute FEATURING Guru Sonpavde
1,701 views
November 22, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

17:48
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Recommended

RENALC-BLADDR-PROSCA 2024

BLADDR 2024 - Hybrid Global Forum on GU Oncology

Wed, Nov 27, 2024
16:05

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views
20:41

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views
29:25

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views
21:08

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

286 views
08:54

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

280 views
15:58

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

529 views
07:40

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

249 views
28:00

New

Review of Bladder Cancer Updates From ESMO 2024

The View on GU | with Lalani & Wallis

A. A. Lalani, C. Wallis

103 views
22:19

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views
20:07

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

246 views
06:32

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

175 views
22:27

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

534 views
22:07

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

344 views
10:19

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

University of Colorado Cancer Center

T. Flaig

337 views
15:28

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

263 views
17:32

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

Kriti Mittal

402 views
14:00

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Insights from 2024 ASCO® GU Annual Meeting

G. Sonpavde

414 views
09:40

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

UCSF School of Medicine

V. Koshkin

262 views
19:30

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Scripps Health

P. Grivas

319 views
16:14

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

175 views
AUTOPLAY